Plan combines up to $25 million in new capital with restructuring of $3 million in existing debt to support commercial execution and manufacturing expansion

Company anticipates positive monthly operating cash flow by the end of Q1 2027

Philip A. Barach to join the Board, bringing financial expertise and a focus on capital discipline

FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced an initial closing generating over $10 million in gross cash proceeds from a private placement of senior secured convertible notes and warrants. The closing is part of a broader recapitalization plan contemplating up to $25 million in new cash investment, including the initial closing, and the restructuring of approximately $3 million in existing indebtedness.

The financing follows significant operating improvements, including a reduction in monthly cash burn of more than $1 million, personnel optimization and a sharper allocation of resources toward revenue-generating opportunities. With a lower operating cost base, purpose-built manufacturing infrastructure and existing cenplacel-L inventory that management estimates represents approximately $40 million in potential sales value, Celularity is focused on converting its scientific and manufacturing assets into revenue and sustained growth.

The Company also announced the appointment of Philip A. Barach to its Board of Directors, bringing financial expertise and an emphasis on capital allocation, operating accountability and stockholder returns.